Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Oncogene, (2023), 10.1038/s41388-022-02585-3)

D. Bello Roufai, A. Gonçalves, T. De La Motte Rouge, S. Akla, C. Blonz, J. Grenier, J. Gligorov, M. Saghatchian, C. Bailleux, H. Simon, I. Desmoulins, Z. Tharin, E. Renaud, M. Bertho, M. A. Benderra, S. Delaloge, L. Robert, P. Cottu, J. Y. Pierga, D. LoiratA. Bertucci, B. Renouf, F. C. Bidard, F. Lerebours

    Résultats de recherche: Contribution à un journal!!Comment/debate

    Résumé

    Correction to: Oncogene, published online 7 January 2023 In this article the affiliation details for Author J. Gligorov were incorrectly given as 7,8,9,10,11,12,13,14, but should have been ‘7, 14’ and for Author J. Y. Pierga were incorrectly given as 1,2,3,4,5,6,7,8,9,10,11,12,13 but should have been 1, 13. In the abstract, the word “data” in the second sentence was misspelled “datda” The original article has been corrected.

    langue originaleAnglais
    Pages (de - à)1417
    Nombre de pages1
    journalOncogene
    Volume42
    Numéro de publication17
    Les DOIs
    étatPublié - 21 avr. 2023

    Contient cette citation